126909-78-2

Basic information

• Product Name: 1-Bromo-3-(cyclopropylmethoxy)benzene
• Synonyms: 1-Bromo-3-(cyclopropylmethoxy)benzene
• CAS NO: 126909-78-2
• Molecular Formula: C₁₀H₁₁BrO
• Molecular Weight: 227.09774
• Mol File: 126909-78-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 1-Bromo-3-(cyclopropylmethoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Bromo-3-(cyclopropylmethoxy)benzene(126909-78-2)
• EPA Substance Registry System: 1-Bromo-3-(cyclopropylmethoxy)benzene(126909-78-2)

Safety Data

• Hazardous Substances Data: 126909-78-2(Hazardous Substances Data)

Usage

Type of compound

brominated aromatic compound

Structure

contains a benzene ring with a bromine atom attached at the 1 position and a cyclopropylmethoxy group attached at the 3 position

Functional groups

bromine atom, aromatic ring, cyclopropylmethoxy group

Applications

useful building block in organic synthesis, particularly in the preparation of pharmaceuticals and agrochemicals

Versatility

the cyclopropylmethoxy group adds further versatility to this compound as a synthetic building block

Potential applications

development of new materials, research tool in organic chemistry

Upstream product

• 591-20-8 3-Bromophenol 
• 7051-34-5 cyclopropylcarbinyl bromide 
• 186581-53-3 diazomethane 
• 41388-50-5 1-(allyloxy)-3-bromobenzene 

Downstream Products

• 1198223-22-1 C₁₅H₂₁N₃O 
• 1198223-20-9 3-(3-(cyclopropylmethoxy)phenyl)pentan-3-amine 
• 1198223-21-0 C₁₅H₂₂O₂ 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

The free fatty acid receptor 1 (FFA1/GPR40) and peroxisome proliferator-activated receptor δ (PPARδ) have been widely considered as promising targets for type 2 diabetes mellitus (T2DM) due to their respective roles in promoting insulin secretion and impr

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

AMINO SULFONYL COMPOUNDS

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.